Antibody-drug combination outperforms standard treatment of advanced triple-negative breast cancer

In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus pembrolizumab resulted in durable responses with improved progression free survival compared to the current standard treatment. The ASCENT-04 study presented today by Dana-Farber Cancer Institute investigators evaluated patients receiving their first treatment for advanced or metastatic triple negative breast cancer that tests positive for the immune checkpoint PD-L1…